The Board of Directors of Tatva Chintan Pharma Chem Limited, in their meeting held on 17 July 2026, approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30 June 2026. The consolidated revenue from operations for the quarter was 1,670.55 Million, compared to 1,341.44 Million in the previous quarter and 1,168.64 Million in the corresponding quarter of the previous year. The profit for the period was 159.81 Million, up from 103.21 Million in the previous quarter and 66.51 Million in the corresponding quarter of the previous year.

Tatva Chintan Pharma Chem Limited, established in 1996 and headquartered in Vadodara, Gujarat, is a prominent manufacturer of specialty chemicals. The company specializes in products such as Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts (ESS), and various pharmaceutical and agrochemical intermediates, serving a global clientele across more than 25 countries.